Cost-effectiveness Analysis of Fidaxomicin versus Vancomycin for the Treatment of Clostridium Difficile Infection in Taiwan
碩士 === 高雄醫學大學 === 醫務管理暨醫療資訊學系碩士在職專班 === 106 === Research Purposes Fidaxomicin is a new class of Clostridium difficile infection (CDI) treatment agent, but the acquisition cost is markedly higher than that of the traditional treatment (oral vancomycin). This study was to investigate the cost-effectiv...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2018
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/uemk67 |